With the exception of acetazolamide (oral/IV) antiglaucoma drugs are administered as eyedrops which have limited systemic absorption in the mother, and pose negligible risk to a breastfed infant. Systemic absorption from eye drops can be minimised by restricting passage into tear ducts immediately after administration (link to technique).
There is limited published evidence of safety or milk levels for the listed antiglaucoma agents.